CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioLineRx Ltd.

BLRX
$15M
Micro Cap
NASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaMODI-IN28 employees

BioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Website

Drugs in Pipeline

10

Phase 3 Programs

1

Upcoming Catalysts

1

Next Catalyst

Aug 13, 2026

10d

Market Overview

Stock performance and key metrics

BLRX News
Catalyst Timeline

1 upcoming, 0 past

EarningsNext

BLRX Earnings Report

Aug 13, 2026STALE

EPS Est: $0.00 | FQ end 2026-06

Drug Pipeline
Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in BioLineRx Ltd.'s drug pipeline?

CatalystAlert tracks 10 drug candidates in BioLineRx Ltd.'s (BLRX) pipeline across Phase 3, Phase 2. Its lead program is BL-8040 1.25 mg/kg + G-CSF (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is BioLineRx Ltd.'s next FDA catalyst?

BioLineRx Ltd.'s (BLRX) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BLRX biotech catalysts?

Add BLRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioLineRx Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply